Kris V Kowdley
Overview
Explore the profile of Kris V Kowdley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
363
Citations
17320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rao N, Moonesinghe R, Shi L, Adams P, Jarvik G, Kowdley K, et al.
Genet Med Open
. 2025 Mar;
3:101959.
PMID: 40034140
Purpose: Type 1 hereditary hemochromatosis (HH) can result in iron overload and liver disease if not detected and treated early. Most cases are found among people homozygous for p.Cys282Tyr variants....
2.
Brookhart M, Mayne T, Coombs C, Breskin A, Ness E, Bessonova L, et al.
Hepatology
. 2024 Dec;
PMID: 39630028
Background And Aims: Primary biliary cholangitis is a rare, progressive liver disease. Obeticholic acid (OCA) received accelerated approval for treating patients with primary biliary cholangitis in whom ursodeoxycholic acid failed,...
3.
Kowdley K, Hirschfield G, Coombs C, Malecha E, Bessonova L, Li J, et al.
Am J Gastroenterol
. 2024 Dec;
120(1):263.
PMID: 39621001
No abstract available.
4.
Bhushan S, Sohal A, Kowdley K
Am J Gastroenterol
. 2024 Oct;
120(1):151-158.
PMID: 39480026
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare, and chronic cholestatic diseases that can progress to liver failure. The goals of treatment are to halt the progression...
5.
Roberts S, Choi W, Worobetz L, Vincent C, Flemming J, Cheung A, et al.
JHEP Rep
. 2024 Oct;
6(10):101168.
PMID: 39380718
Background & Aims: Biochemical response to ursodeoxycholic acid (UDCA) therapy is associated with good prognosis in people living with primary biliary cholangitis (PBC). Biochemical response is typically assessed early in...
6.
Sohal A, Casanova L, Kowdley K
ACG Case Rep J
. 2024 Oct;
11(10):e01484.
PMID: 39372916
Tirzepatide is the first dual incretin glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor activator approved for the management of type II diabetes mellitus. This drug was also recently approved by the...
7.
Kowdley K, Hirschfield G, Coombs C, Malecha E, Bessonova L, Li J, et al.
Am J Gastroenterol
. 2024 Aug;
120(2):390-400.
PMID: 39140490
Introduction: Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in patients with...
8.
Huang D, Wilson L, Behling C, Amangurbanova M, Kleiner D, Kowdley K, et al.
Hepatology
. 2024 Jul;
PMID: 39028908
Background And Aims: There are limited data on the progression of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in people with type 2 diabetes mellitus (T2DM) versus those...
9.
Levy C, Caldwell S, Mantry P, Luketic V, Landis C, Huang J, et al.
Clin Transl Gastroenterol
. 2024 Jul;
15(8):e00744.
PMID: 38976363
Introduction: This proof-of-concept, open-label phase 1b study evaluated the safety and efficacy of cilofexor, a potent selective farnesoid X receptor agonist, in patients with compensated cirrhosis due to primary sclerosing...
10.
Kowdley K, Levy C, Jones D
N Engl J Med
. 2024 May;
390(20):1935-1936.
PMID: 38810196
No abstract available.